Human UMP/CMP kinase (EC 2.7.4.14) is responsible for phosphorylation of CMP, UMP, and dCMP and also plays an important role in the activation of pyrimidine analogs, some of which are clinically useful anticancer or antiviral drugs. Previous kinetic data using recombinant or highly purified human UMP/CMP kinase showed that dCMP, as well as pyrimidine analog monophosphates, were much poorer substrates than CMP or UMP for this enzyme.
INTRODUCTION
UMP/CMP kinase (EC 2.7.4.14), which phosphorylates CMP, UMP, and dCMP to their respective diphosphates, is crucial for cellular nucleic acid synthesis. The synthesis of pyrimidine nucleotides, in both de novo and salvage pathways, requires this enzyme to produce diphosphates from the monophosphate forms (Van Rompay et al, 2000) . Recently, a conditional lethal mutant isolated from Saccharomyces cerevisiae was identified to be caused by mutated UMP/CMP kinase, indicating the essentiality of this enzyme in the survival of this organism and possibly in mammalian cells (Liljelund and Lacroute, 1986) .
UMP/CMP kinase also plays an important role in the activation of deoxycytidine analogs, many of which are important anti-cancer and anti-viral agents (Cheng, 2001; Galmarini et al, 2001 Galmarini et al, & 2002 . For example, 1-β-D-arabinofuranosylcytosine (ara-C) is commonly used to treat hematological malignancies (Grant, 1998) . 2', 2'-difluorodeoxycytidine (gemcitabine) has been shown to be active against pancreatic cancer and several other solid tumors (Hui and Reitz, 1997; Noble and Goa, 1997) .
β-L-dioxaolanecytidine (L-OddC), a deoxycytidine analog with an unnatural Lconfiguration, is currently under active clinical investigations because of The requirement for Mg in the kinase activity was much more stringent in dCMPK reaction than in CMPK reaction. Under 0 mM of Mg, CMPK and dCMPK activities were ~70 and 0 µ mol/min/mg protein, respectively. The optimum of CMPK reaction (in the presence of 2 mM ATP) was achieved when Mg was 2 mM, and further increases of Mg concentration resulted in a mild dose-dependent inhibition ( Fig. 1-C) . In contrast, the optimum of dCMPK reaction was at 4 to 6 mM of Mg, i.e. there was 2~ 4 mM of free Mg in reactions.
Further increase of free Mg might have some inhibitory effect on dCMPK activity ( Fig. 1-C) .
Change of ATP/Mg leads to a change of kinetic properties of human recombinant UMP/CMP kinase. Our preliminary observations showed that free ATP and excessive amount of ATP/Mg have a significant inhibition on dCMPK activity but not on CMPK activity of recombinant human UMP/CMP kinase, and free Mg has enhancing and suppressing effects on dCMPK activity and CMPK activity, respectively. We wondered whether an increase of free Mg and a decrease of free ATP would change the kinetics of UMP/CMP kinase and make it more favorable to the phosphorylation of dCMP. The Km and relative activity in terms of phosphorylating dCMP and CMP were evaluated under different concentrations of ATP/Mg, shown in Table 1 .
This article has not been copyedited and formatted. The final version may differ from this version. When ATP/Mg concentrations were changed from 8/8 mM, which was quite unfavorable to dCMP phosphorylation, to 0.1/2 mM or 0.5/2 mM, which was relatively more favorable to dCMP phosphorylation, the Kms for dCMP decreased and the relative activity increased. As a result, the relative efficiency for this enzyme to phosphorylate dCMP increased 4.9-fold. On the other hand, the relative efficiency of recombinant protein to phosphorylate CMP was also increased for 4.9-fold by changing ATP/Mg from 8/8 mM to 0.1/2 mM (Table 1) . In other words, the enzyme kinetic studies demonstrated that the change of ATP/Mg had a comparable and parallel impact on CMPK and dCMPK activities (Table 1) showed to be a non-competitive inhibitor of dCMP reaction (Fig 3) . The Ki values for CMP to inhibit dCMP phosphorylation were 4 to 6 -fold higher than its own Km values (Table 2) . UMP was also a noncompetitive inhibitor of dCMP reaction (data not shown). The data suggests that CMP or UMP inhibits recombinant protein from phosphorylating dCMP through sites other than the site responsible for its own binding site. Interestingly, dCMP was found to be a competitive inhibitor of CMP phosphorylation (Fig. 4) , and the Ki values for dCMP to inhibit CMPK reaction were similar to its own Km values (Table 3 ).
In summary, the enzyme inhibition studies showed that the active sites for dCMP and CMP of human recombinant UMP/CMP kinase cannot be identical.
eukaryotic UMP/CMP kinases is that bacterial CMP kinase can phosphorylate dCMP nearly as well as CMP (Serina et al, 1995; Bucurenci et al, 1996) . The different kinetic characteristics and structure biology studies of UMP or CMP kinases from different species help delineate the molecular mechanisms responsible for substrate specificity and catalytic phosphorylation of this enzyme (Muller-Dieckmann and Schulz, 1994 & 1995; Serina et al, 1995; Wiesmuller et al, 1995; Bucurenci et al, 1996; Scheffzek et al, 1996; Briozzo et al, 1998; Hutter and Helms, 2000; Bertrand et al, 2002; Yu et al, 2003) . For example, it has been shown that an approximate 40-amino acid residue insertion in the NMP binding domain is common in CMP kinases from bacteria (Serina et al, 1995; Bucurenci et al, 1996; Briozzo et al, 1998) . In addition, the crystal structure and mutagenesis studies of E. coli CMP kinase showed that the serine101-residue located in this NMP-binding domain insertion plays a critical role in determining the preference for dCMP (Berstrand et al, 2002) .
It is worthy to note that previous structural studies of these non-mammalian UMP/CMP kinases did not reveal a dimer structure.
In this report, we provide kinetic data on human UMP/CMP kinase indicating that the kinetically active sites of this enzyme to interact with either dCMP or CMP should be different. The fact that there may be 2 distinct
This article has not been copyedited and formatted. The final version may differ from this version. binding sites for CMP or dCMP could be explained by 2 hypothetical models for the phosphorylation action of this enzyme. One possibility is the "asymmetric dimer" model, in which the enzyme is composed of two subunits, representing two catalytically active sites: one for dCMP (and most pyrimidine nucleoside analog monophosphates) and the other for CMP (as well as UMP and FUMP). Another possibility is that human UMP/CMP kinase exists in two different monomers: one is preferential for CMP phosphorylation and the other is preferential for dCMP phosphorylation (Fig.6 ). There might be certain equilibrium between the 2 hypothetic models. Interestingly, our data also indicate that binding of different substrates to the site other than their own catalytically active site does exist. For example, we showed that while CMP is a non-competitive inhibitor of dCMP phosphorylation, dCMP is a competitive inhibitor of CMP phosphorylation. This can be envisioned as dCMP interacts with the site which is catalytically active for CMP, in addition to its own active site.
Human UMP/CMP kinase is the only known enzyme to phosphorylate dCMP in human cells. However, given the facts that dCMP exists in a hundred-fold less amount than CMP or UMP in cells (Traut, 1994a) and that dCMP is phosphorylated by recombinant human UMP/CMP kinase with an This article has not been copyedited and formatted. The final version may differ from this version. efficiency 100-fold less than UMP or CMP (Van Rompay et al, 1999; Liou et al, 2002; Pasti et al, 2003) , it is almost impossible for dCMP to be phosphorylated in cells if all these naturally occurring pyrimidine monophosphates compete with each other at the same binding site of the enzyme. Similarly, the phosphorylation of pyrimidine nucleoside analog monophosphates, including ara-CMP, gemcitabine MP, and L-OddCMP, by human UMP/CMP kinase could also be very difficult in cells because the efficiency for these analog monophosphates to be phosphorylated by this enzyme is only comparable to or even less efficient than the phosphorylation of dCMP (Liou et al, 2002) .
Our proposed models, either asymmetric dimer or coexisting different monomers, indicate that it is difficult for CMP or UMP to completely inhibit dCMP phosphorylation due to the non-competitive nature of this inhibition.
Furthermore, the physiological concentration of intracellular ATP is 3.1± 1.7 mM, and that of Mg is 1.1 mM in free form and 8 mM in complex form (Traut TW 1994) . The concentration ranges that we studied were within the ranges mentioned above. In addition, the concentrations of nucleotides or metal ions are known to vary in different sub-cellular localizations due to compartmentalization or by different regulatory mechanisms. In this report, we showed that changing the concentrations of ATP and/or Mg would make This article has not been copyedited and formatted. The final version may differ from this version. to be a homodimeric globular protein (Ostermann et al, 2000) . Human deoxycytidine kinase (dCK), which is responsible for the phosphorylation of natural deoxynucleosides and numerous nucleoside analogs, has been shown to be a homodimeric globular protein, too (Sabini et al, 2003) . In an early literature studying the pyrimidine monophosphate kinase of human leukemic cells, the authors used gel filtration chromatography and found out that some dCMP kinase activity resided in "aggregated" proteins, i.e. those proteins with an estimated molecular weight 2 to 3 fold higher than the molecular weight from the major activity peak (Hande and Chabner, 1978) . Another early There was excessive free ATP in the reactions when ATP was more than 2 mM. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. 
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